Niagen Bioscience, Inc. — Director's Dealing 2010

Apr 6, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2009-05-13

Reporting Person: Jaksch Frank L Jr (Director, Chief Executive Officer, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-05-13	Stock Option (Right to buy)	$.050	A	100000	Acquired	2019-05-13	Common Stock (100000)	Direct

Footnotes

F1: 25,000 options become exercisable May 13, 2010 and 2083 become exercisable each month for 36 months thereafter with 2084 becoming exercisable every third month.